Dabur India has completed the acquisition of Fem Care Pharma, a leading player in the women's skin care products market. The transaction was approved at a board meeting held in Mumbai.

Dabur had earlier acquired 72.15 per cent of Fem for Rs 203.7 crore in an all-cash deal. After obtaining the regulatory approvals, Dabur acquired additional 20 per cent stake for Rs 54 crore through an Open Offer. With the completion of this transaction, Fem Care Pharma is now a subsidiary of Dabur India.

"With this acquisition, Dabur has consolidated its position as a leading Indian consumer goods company with presence across key categories like skin care, hair care, oral care, health care and foods. The completion of this acquisition represents a significant step for Dabur in our strategy to accelerate growth in our core FMCG business. We are now focused on quickly seizing the attractive opportunities this transaction has created for us to increase top-line growth as well as achieving significant cost synergies," said Sunil Duggal., chief executive officer, Dabur India.

Fem Care Pharma, which has a leadership position in the fairness bleach category and a strong market position in hair removal and liquid soap category, is best known for its brand 'FEM'. The other brands in its portfolio include Oxybleach cream, Botanica anti-ageing cream, Stratum colour protecting hair conditioners and SAKA men's bleach. The company also has a sizeable international market presence in markets such as Yemen, Maldives, Mauritius, Malaysia, UAE, Oman etc.

"Besides an entry into the high-growth skin care market with an established brand name FEM, this transaction also offers Dabur a strong platform to enter newer product categories and markets. As with our previous acquisition and subsequent integration of Balsara's Hygiene and Home products businesses, the Fem Care Pharma transaction too would offer substantial synergies for expanding the reach of Fem's brands in all our geographies," Duggal added.